Holen Sie sich die Stockscreener-App
25.24
2.73%
0.67
Handel nachbörslich:
25.19
-0.05
-0.20%
Schlusskurs vom Vortag:
$24.57
Offen:
$24.66
24-Stunden-Volumen:
3.64M
Relative Volume:
3.44
Marktkapitalisierung:
$1.47B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
2.2218
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
-42.18%
1M Leistung:
-41.91%
6M Leistung:
-16.17%
1J Leistung:
-54.56%
1-Tages-Spanne:
$23.00
$25.94
1-Wochen-Bereich:
$22.24
$46.00
52-Wochen-Spanne:
$22.24
$62.45
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
25.24 | 1.43B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
9 Oversold Biotech Stocks to Invest In - Insider Monkey
The week in pharma: action, reaction and insight – week to November 21 - The Pharma Letter
Agios rebounds as Leerink upgrades to Outperform on selloff - MSN
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - MSN
AGIO: JP Morgan Lowers Price Target to $20.00 -- Maintains Neutral Rating | AGIO Stock News - GuruFocus
Agios Pharma stock price target lowered to $48 at H.C. Wainwright on mixed trial data - Investing.com Canada
Leerink Partners upgrades Agios Pharma stock on thalassemia potential By Investing.com - Investing.com Canada
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - Yahoo Finance
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story - Yahoo Finance
Agios slumps on mixed Phase III trial of mitapivat in sickle cell disease - The Pharma Letter
Agios stock rebounds as Leerink upgrades (AGIO:NASDAQ) - Seeking Alpha
Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexesStock Surge & Safe Capital Allocation Plans - newser.com
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug - Stocktwits
Agios Pharma stock plunges on mixed Pyrukynd sickle cell trial results - Investing.com India
AGIO: Leerink Partners Upgrades Rating, Lowers Price Target | AG - GuruFocus
AGIO: Goldman Sachs Lowers Price Target, Maintains Neutral Ratin - GuruFocus
Leerink Partners upgrades Agios Pharma stock on thalassemia potential - Investing.com India
Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs - TipRanks
Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Tria - GuruFocus
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
RBC Downgrades Agios Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $28 From $57 - MarketScreener
Leerink Partners Upgrades Agios Pharmaceuticals to Outperform From Market Perform, PT is $34 - MarketScreener
AGIO: HC Wainwright Lowers Price Target But Maintains Buy Rating - GuruFocus
Published on: 2025-11-20 04:28:25 - newser.com
Published on: 2025-11-20 00:18:11 - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
Published on: 2025-11-19 21:36:35 - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsOil Prices & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-11-19 18:19:52 - newser.com
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results By Investing.com - Investing.com South Africa
Agios Makes Case For Pyrukynd Approval In SCD Despite Mixed Phase III Results - Citeline News & Insights
Will Agios Pharmaceuticals Inc. stock see PE expansionProduct Launch & High Return Trade Opportunity Guides - newser.com
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results - Markets Financial Content
Agios planning sNDA on mixed sickle cell data for mitapivat - BioWorld MedTech
This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily
Agios reports mixed results in sickle cell disease trial of mitapivat - Investing.com Nigeria
Agios Pharma: Study Fail May Affect Mitapivat TDT ApprovalExpect More Volatility (AGIO) - Seeking Alpha
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results - Investing.com UK
Agios Shares Plunge 50% After Mixed Phase 3 RISE UP Results For Mitapivat - Nasdaq
Why Shares in Agios Pharmaceuticals Got Crushed Today - AOL.com
Agios Pharmaceuticals (AGIO) Faces Downgrade Amid Sickle Cell Drug Data - GuruFocus
Agios Pharma stock rating downgraded by RBC Capital after mixed trial data - Investing.com
Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool
RBC downgrades Agios to Sector Perform after mitapivat ‘falls short’ - TipRanks
Agios Pharmaceuticals (AGIO) Faces Uncertainty After Trial Resul - GuruFocus
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results - Benzinga
Agios Pharmaceuticals (AGIO) Sees Sharp Decline in Stock Price - GuruFocus
Agios shares fall on mixed sickle cell results for blood disease drug - BioPharma Dive
Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga
Agios shares tumble on mixed results for sickle cell drug trial - MSN
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):